Episealer® presentation at the ISKSAA Global Summit in Leeds, UK on June 21, 2018

Episurf Medical (NASDAQ: EPIS B) today announces that Professor Leif Ryd will speak at the ISKSAA Global Summit in Leeds, UK on June 21, 2018. The topic is “Customized femoral resurfacing metal implant for focal chondral lesions”. ISKSAA Global Summit, this time in Leeds, is the annual main event of ISKSAA, the International Society for Knowledge for Surgeons on Arthroscopy and Arthroplasty. The ISKSAA organization, originating from India, launched its global congresses in 2012 and this is the first time the annual gathering is arranged in Europe.

“We are very happy for this opportunity to present at the ISKSAA congress since it has over 500 delegates with about 400 of them from India. Episurf Medical is in the process of establishing a presence in Asia, and India has been identified as one of our future key markets”, says Pål Ryfors CEO Episurf Medical.

For more  information, please contact:

Pål Ryfors, CEO, Episurf Medical

Tel:+46 (0) 709 62 36 69

Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Tags:

About Us

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalized treatment alternatives. Episurf Medical’s Episealer® personalized implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.